Short answer: Per the FDA label (2.2), Rybelsus starts at 3 mg once daily for days 1–30, a dose the label says is not effective for glycemic control, then 7 mg once daily for days 31–60. From day 61, the label's schedule either stays at 7 mg or increases to 14 mg if additional glycemic control is needed.
Per label section 1, Rybelsus (and Ozempic tablets) are indicated in adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in those at high risk for these events. This page summarizes the current FDA prescribing information (revised 1/2026). It is not personalized medical advice; your prescriber sets your dose.
The label's dosing schedule (label section 2.2):
| Period | Dose | Label note |
|---|---|---|
| Days 1–30 | 3 mg once daily | Starting (initiation) dosage; the label says it is not effective for glycemic control |
| Days 31–60 | 7 mg once daily | Escalation dosage |
| Day 61 onward | 7 mg once daily, or 14 mg once daily | Stays at 7 mg if no additional glycemic control is needed; 14 mg if additional glycemic control is needed |
Maintenance: The label maintenance dosages are 7 mg or 14 mg once daily from day 61 onward, with 14 mg used if additional glycemic control is needed (2.2). The label refers to 14 mg as the maximum recommended human dose of semaglutide tablets (13.1).
Below is the label schedule laid out period by period, using the earliest timing the label allows. The label lets prescribers stay at a step longer, so a real calendar is often slower. The blank columns are for your own record.
| Period | Label dose | Date | Site / time | Weight | Notes |
|---|---|---|---|---|---|
| Days 1–30 | 3 mg once daily | ||||
| Days 31–60 | 7 mg once daily | ||||
| Day 61 onward | 7 mg once daily, or 14 mg once daily if additional glycemic control is needed |
Printing this page prints the schedule and calendar without the site navigation.
| Product | Tablet strength | Pack | Description |
|---|---|---|---|
| Rybelsus | 3 mg | Bottle of 30 tablets | White to light yellow, oval, debossed "3" on one side and "novo" on the other |
| Rybelsus | 7 mg | Bottle of 30 tablets | White to light yellow, oval, debossed "7" on one side and "novo" on the other |
| Rybelsus | 14 mg | Bottle of 30 tablets | White to light yellow, oval, debossed "14" on one side and "novo" on the other |
| Ozempic tablets | 1.5 mg | Bottle of 30 tablets | White to light yellow, round, debossed "1.5" on one side and "novo" on the other |
| Ozempic tablets | 4 mg | Bottle of 30 tablets | White to light yellow, round, debossed "4" on one side and "novo" on the other |
| Ozempic tablets | 9 mg | Bottle of 30 tablets | White to light yellow, round, debossed "9" on one side and "novo" on the other |
The label reports these rates from placebo-controlled trials (label section 6.1, Table 2). Percentages are the share of trial participants who reported each reaction.
| Adverse reaction | Placebo (N=362) | Semaglutide tablets 7 mg (N=356) | Semaglutide tablets 14 mg (N=356) |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Abdominal pain | 4% | 10% | 11% |
| Diarrhea | 4% | 9% | 10% |
| Decreased appetite | 1% | 6% | 9% |
| Vomiting | 3% | 6% | 8% |
| Constipation | 2% | 6% | 5% |
When do they happen? Per the label, the majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation. Gastrointestinal adverse reactions overall occurred in 21% (placebo), 32% (7 mg), and 41% (14 mg), and led to discontinuation in 1%, 4%, and 8%, respectively (6.1).
The label also carries warnings that are not in this table (for example, a boxed warning or pancreatitis and gallbladder warnings where applicable). Read the full label linked under Sources, and report side effects to your prescriber.
The label's switching table (label section 2.3, Table 1; 2.4). Switching is a prescriber decision.
| RYBELSUS | OZEMPIC Tablets |
|---|---|
| 7 mg orally once daily | 4 mg orally once daily |
| 14 mg orally once daily | 9 mg orally once daily |
Per the label, a missed dose is skipped and the next dose is taken the following day. The label also says not to take more than one tablet per day. (label section 2.1) The full walk-through is on the Rybelsus missed-dose page.
The label describes one tablet once daily on an empty stomach in the morning, with up to 4 ounces of plain water and no other liquids, swallowed whole (not split, crushed, chewed, or dissolved). It then describes waiting at least 30 minutes before eating, drinking other beverages, or taking other oral medications. (label section 2.1)
A simple log makes each titration step easier to talk through with your prescriber. These are the things worth writing down, and how Dose Track handles them:
Your log stays on your phone. See GLP-1 tracking in Dose Track for the full feature list.
Reviewed as of . Section numbers above refer to the FDA prescribing information.
All GLP-1 brand guides · GLP-1 tracking · Supported medications